Related Experiment Videos
Group B streptococci during pregnancy and infancy
1Department of Pediatrics, University Hospital Freiburg, Freiburg, Germany. berner@kikli.ukl.uni-freiburg.de
Insights
Group B Streptococcus (Streptococcus agalactiae) infections remain a perinatal concern. New vaccines and understanding of immune responses offer future prevention strategies despite antibiotic resistance challenges.
Area of Science:
- Obstetrics and Gynecology
- Neonatal Medicine
- Infectious Diseases
Background:
- Group B Streptococcus (GBS) remains a significant perinatal pathogen, despite reduced neonatal invasive infections due to maternal antimicrobial prophylaxis.
- Current prophylaxis strategies fail to prevent preterm delivery or late-onset GBS sepsis.
- Increasing global antibiotic resistance complicates GBS management.
Purpose of the Study:
- To review advances in GBS prevention and treatment strategies.
- To highlight the potential of new conjugate vaccines and virulence factor research.
- To discuss the immune response pathways relevant to GBS infection.
Main Methods:
- Review of recent scientific literature on Group B Streptococcus.
- Analysis of developments in conjugate vaccine technology.
- Examination of research into GBS virulence factors and host immune responses.
Main Results:
- Significant progress has been made in developing GBS conjugate vaccines.
- Research has identified key virulence factors and immune pathways involved in GBS pathogenesis.
- Some novel strategies show promise for future clinical application.
Conclusions:
- Despite prophylaxis successes, GBS remains a critical perinatal issue.
- Advances in vaccine development and understanding GBS immunity offer hope for improved prevention.
- Future clinical practice may incorporate new GBS interventions.
Abstract:
Group B streptococcus (Streptococcus agalactiae) is still of great relevance in the perinatal period, although maternal antimicrobial prophylaxis has significantly reduced the rate of culture-confirmed invasive infection in neonates. This strategy, however, raises considerable concern because preterm delivery or late-onset sepsis cannot be prevented, and antibiotic resistance is increasing worldwide. Several advances in the development of conjugate vaccines and in research on virulence factors and pathways involved in the immune response to group B streptococcus have been accomplished, some of which might reach clinical practice in the near future.